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cells via the IL-4 receptor and the Stat6 signaling path-1Tumorimmunology Program
way (Kuhn et al., 1991; Kopf et al., 1993; Kaplan et al.,German Cancer Research Center (DKFZ)
1996a; Shimoda et al., 1996; Takeda et al., 1996;D-69120 Heidelberg
O’Garra, 1998). Transcription factors such as c-maf (Ho2Institute for Medical Microbiology
et al., 1996, 1998) and GATA3 (Zheng and Flavell, 1997),University of Marburg
along with NF-AT (Hodge et al., 1996a) and NIP45D-35037 Marburg/Lahn
(Hodge et al., 1996b), have been shown to play a majorGermany
role in the transition toward Th2 cells. IL-12 exerting its
effect via the IL-12 receptor and the Stat4 signaling
pathway appears to be the major inducer of Th1 devel-Summary
opment (Kaplan et al., 1996b; Magram et al., 1996; Thier-
felder et al., 1996). Furthermore, the transcription factorPolarization of CD4 T helper cells toward either a
T-bet was found to be critically involved in murine Th1Th1 or Th2 response can significantly influence host
development and in transactivation of the IFN- geneimmunity to pathogens. IL-4 and IFN- are the signa-
(Szabo et al., 2000).ture cytokines of Th2 and Th1 cells, respectively. IFN-
The separation of mature CD4 cells into Th1 andwas shown to assist Th1 development by promoting
Th2 subsets is underscored by the fact that in manyIL-12 and IL-12 receptor expression. So far, direct in-
autoimmune and infectious diseases one T helper cellfluence of Th2 cytokine expression by IFN- has not
phenotype is predominant (Romagnani, 1994). This pre-been described. We show here that IFN- directly sup-
dominance is attained by positive and negative feed-presses IL-4 gene expression. IRF-1 and IRF-2 induced
back loops acting directly or indirectly between the twoby IFN- bind to three distinct IL-4 promoter sites
subsets. For example, IL-4 secreted by mature Th2 cellsand function as transcriptional repressors. Our data
directly drives the polarization of naive Thp toward Th2demonstrate a direct negative feedback of IFN- on
cells (Paul and Seder, 1994), whereas IL-10, another Th2expression of the Th2 cytokine gene IL-4 and, thus,
cytokine, indirectly inhibits the polarization toward Th1provide evidence for another important mechanism by
cells by repressing the secretion of IL-12 (the major Th1-which IFN assists Th1 and attenuates Th2 responses.
inducing cytokine) by activated macrophages (Fioren-
tino et al., 1991). Moreover, IL-4 represses the expres-Introduction
sion of the IL-12 receptor on developing cells, screwing
them toward Th2 cells (Szabo et al., 1997). Thus, Th2Mature CD4 T lymphocytes can be divided into two
cells reinforce their own phenotype while repressing thedistinct subpopulations named Th1 and Th2 based on
Th1 phenotype via IL-4 and IL-10. Recently, anothertheir pattern of cytokine expression (Abbas et al., 1996;
feedback loop was added to the cytokine network by aMosmann and Coffman, 1989). The Th1 subpopulation
study showing that in the murine system IL-4 promotesis characterized by the production of IFN-, IL-2, TNF,
dendritic cells to produce bioactive IL-12, thereby caus-and LT, cytokines involved in cell-mediated immune re-
ing differentiation of naive cells toward Th1 cells andsponses such as delayed-type hypersensitivity and
providing a negative feedback on the Th2 phenotype
macrophage activation. In contrast, the Th2 subpopula-
(Holtschke et al., 1996). In contrast, Th1 cells promote
tion produces IL-4, IL-5, and IL-10 and plays a major
their own subset via IFN- which induces IL-12 produc-
role in antibody-dependent immune responses such as tion from activated macrophages and the expression of
allergic responses via activation of B cells, mast cells, the IL-12 receptor on activated Thp cells (Szabo et al.,
and eosinophils (Mosmann et al., 1986; Paul and Seder, 1997; Ma et al., 1996). However, feedback loops derived
1994). Th2 cytokines such as IL-4 are central to B cells from Th1 cells that directly negatively regulate Th2 cells
switching to IgE antibody production, and IgE-depen- have not yet been described.
dent inflammatory reactions are generally characteristic In this study, we have investigated whether expres-
of atopic disorders like asthma and rhinoconjunctivitis sion of the Th2 cytokine IL-4 is influenced by IFN-.
(Arthur and Mason, 1986). Here we show that IFN- directly downregulates IL-4
Since the particular cytokines produced during an expression in primary human T lymphocytes. We found
immune response determine recruitment and activation that suppression of IL-4 expression by IFN- is mediated
of other immune cells, the progression and outcome of by IRF-1 and IRF-2. Previously, we have identified an
autoimmune as well as infectious diseases is influenced IRF-2 binding site in the IL-4 promoter (Li-Weber et al.,
by the cytokine milieu (Romagnani 1994; Lucey et al., 1994). In this study, we identified two extra novel IRF
1996). The Th1 and Th2 subsets differentiate from naive binding sites. One of these IRF binding sites is located
CD4 Th precursor (Thp) cells. Significant progress has in the region which was previously shown to function
been made in understanding cytokines and transcription as a T cell-specific negative regulatory element (Li-
Weber et al., 1992). We show here that IRF-2 and IRF-1
both function as repressors of the IL-4 promoter activity.3Correspondence: m.li-weber@dkfz-heidelberg.de
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Results
IFN- Downregulates IL-4 Protein and mRNA Levels
IFN- is the signature cytokine of Th1 cells and promotes
the polarization of naive Th cells toward Th1 cells. There-
fore, we wondered whether IFN- influenced the level
of IL-4 expression. To clarify this question, we isolated
primary human peripheral blood T lymphocytes of
healthy donors and activated the cells via TCR/CD3 and
CD28 in the absence or presence of IFN-. The superna-
tants were analyzed for IL-4 production by ELISA, and
the cells were collected for determination of IL-4 mRNA
expression levels. Since primary human T lymphocytes
produce large amounts of IFN- upon activation, we also
added IFN- neutralizing antibodies into the medium to
investigate the effect of IFN- on IL-4 production. As
shown in Figure 1, IL-4 protein secretion was induced
upon activation of the primary T cells by -CD3 and
-CD28. In the presence of IFN-, IL-4 secretion was
significantly reduced. In contrast, in the presence of
the IFN- neutralizing antibodies IL-4 production was
increased (Figure 1A). Similar results were obtained
when primary T cell stimulation was extended to 6 days
before restimulation by -CD3 (data not shown).
To test whether the reduced IL-4 protein levels in the
supernatants were due to reduction of IL-4 transcripts
we measured IL-4 mRNA levels. As shown in Figure 1A,
IL-4 mRNA levels were reduced by the addition of INF-
but increased in the presence of IFN- neutralizing anti-
bodies. Secretion of the IL-4 protein and expression
of the IL-4 mRNA were repressed by IFN- in a dose-
dependent manner (Figure 1B). The decreased IL-4 lev-
els were not due to a decrease in cell numbers. Trypan
blue exclusion showed comparable numbers of survival
cells in all groups. The IFN--induced repression of IL-4
mRNA and IL-4 protein production also did not depend
on CD28 costimulation. Stimulation of primary T lympho- Figure 1. Effect of IFN- on IL-4 Secretion and IL-4 mRNA Levels
cytes with -CD3 antibody alone showed a similar re- in Activated Primary Human T Lymphocytes
duction of IL-4 by IFN- (data not shown). (A) Primary human CD4 T lymphocytes were either untreated ()
To further investigate the effect of INF- on IL-4 ex- or stimulated () with -CD3 plus -CD28 in the absence () or
presence () of 100 U IFN- or 3 g/ml IFN- neutralizing antibodypression, we performed kinetics. At the initial phase (6
as indicated. After 48 hr culture, the supernatant was removed tohr) of T cell activation, no influence of IFN- on IL-4
measure IL-4 production by ELISA, and the cells were collected forprotein expression levels was seen. A slight but substan-
RNA isolation and subsequently for RT-PCR analysis of IL-4 mRNAtial increase in IL-4 production was observed after 12
levels. Comparable cell numbers were determined by trypan blue
hr activation of the T lymphocytes in the presence of exclusion.
-IFN- antibody. The effect of IFN- on IL-4 expression (B) Primary human CD4 T lymphocytes were treated as in (A) for
48 hr in the presence of different concentrations of IFN- as indi-became pronounced after 24 hr (Figure 2A). Correspond-
cated. The supernatant and the cells were analyzed for IL-4 produc-ingly, IL-4 mRNA levels showed similar kinetics to those
tion and IL-4 mRNA levels as in (A).observed on the IL-4 protein expression level (Figure
2B). IFN- induced repression of IL-4 mRNA expression
lasted at least up to 96 hr poststimulation. The IFN-- IRF-2 at the 200/180 region (referred to hereafter as
induced repression was specific for IL-4 since, for exam- IRF-B site) in the IL-4 promoter. Mutation at this site
ple, IL-2 levels were not affected (Figure 2C). Taken resulted in a 2-fold increase in promoter activity upon
together, these data demonstrate that IFN- can repress PMA/ionomycin or PMA/PHA stimulation of Jurkat T
IL-4 production in peripheral T cells. cells (Li-Weber et al., 1994). Therefore, we reasoned that
binding of IRFs to the IL-4 promoter may be a possible
mechanism for IFN--mediated IL-4 repression. BesidesIRF-1 and IRF-2 Bind to Three Sites
of the IL-4 Promoter the IRF-B site, we further identified two additional poten-
tial IRF binding sites located in the 304/280 regionSince IL-4 mRNA levels were reduced in the presence
of IFN-, we further investigated the molecular mecha- (referred as IRF-A site) and the 112/92 (referred as
IRF-C site) of the IL-4 promoter, respectively. Interest-nism of IFN--mediated suppression. Previously, we
have identified a binding site for the constitutive factor ingly, IRF-A is located within the region which was pre-
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Figure 2. Kinetic Analysis of the Influence of IFN- on IL-4 Expression in Primary Human T Lymphocytes
(A) Primary human T lymphocytes were stimulated with -CD3 plus -CD28 in the presence or absence of 100 U IFN- or 3 g/ml IFN-
neutralizing antibody for the indicated periods. The supernatant was removed for ELISA analysis of IL-4 protein. Results are representative
of experiments conducted with cells from three donors. Mean and SD are shown.
(B) The cells treated in (A) were collected for RNA isolation and subsequently for RT-PCR analysis of IL-4 mRNA levels.  and  indicate
without or with treatment as indicated. Expression of IL-4 mRNA is suppressed by IFN-.
(C) To control the specificity of the effect of IFN- on IL-4 production, the supernatant was also subjected to ELISA for analysis of the IL-2
protein levels.
viously shown to exert a T cell-specific negative effect blood T lymphocytes untreated or stimulated by -CD3
and -CD28 in the presence or absence of IFN- wereon IL-4 promoter activity (Li-Weber et al., 1992). To in-
vestigate whether these potential IRF sites are recog- used in EMSA. IFN--inducible binding activities were
found on all three DNA probes (Figure 3B). The IFN--nized by IRF proteins, we used in vitro-translated IRF-1
and IRF-2 proteins in EMSA. The specificity of the IRF-1 inducible proteins became detectable after 6 hr IFN-
treatment, and the binding activity increased further,and IRF-2 proteins was controlled by using a DNA probe
containing the consensus IRF site and an unrelated DNA reaching a maximum in 24 hr. In contrast, activation of
T lymphocytes with -CD3 and -CD28 antibodies alonefragment as a negative control. As shown in Figure 3A,
IRF-1 and IRF-2 proteins bind to all three promoter sites did not influence the binding activity. INF--induced
complexes were supershifted by -IRF-1 and -IRF-2indicating that all three sites interact with IRF proteins.
We next investigated whether the IL-4 IRF sites inter- antibodies, demonstrating that IRF-1 and IRF-2 bind to
these sites (Figure 3C). The specificities of the -IRF-1act with IRFs induced by IFN- in activated T cells.
Nuclear proteins isolated from freshly isolated human and -IRF-2 antibodies were controlled by the in vitro-
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Figure 3. Binding of IRF-1 and IRF-2 Proteins to Three Distinct IL-4 Promoter Regulatory Elements
(A) IRF-1, IRF-2, and luciferase (as a control) proteins were prepared by in vitro transcription/translation and used in EMSA. The previously
identified IL-4 IRF-2 binding site IRF-B (Li-Weber et al., 1994) and two novel potential IRF binding sites, IRF-A (located in the previously
identified negative regulatory element [NRE] region [Li-Weber et al., 1992]) and IRF-C, were used as probes. An oligonucleotide containing
an IRF consensus (IRF Cons.) binding sequence and an unspecific oligonucleotide (non-spe.) were used as controls.
(B) Inducible binding of IRFs to the IL-4 IRF binding sites upon IFN- stimulation. EMSA was performed using nuclear extracts of primary
human T lymphocytes cultured for 24 hr without () or with () -CD3 and -CD28 antibodies in the absence () or presence () of 100 U
IFN-. The IL-4 IRF-A, IRF-B, and IRF-C oligonucleotides were used as probes as indicated. The IFN--inducible complexes are indicated by
arrows.
(C) The IFN--inducible complexes were analyzed by -IRF-1- and -IRF-2-specific antibodies. Nuclear extracts from primary human T
lymphocytes treated with IFN- for 24 hr were used in EMSA. The specific IRF/DNA complexes and the supershifted bands are indicated by
arrows.
(D) IFR-1 and IRF-2 proteins prepared from the in vitro transcription/translated system were used to control the specificity of the antibodies
used. The IRF consensus sequence was used as the probe.
translated IRF proteins in EMSA. As shown in Figure 3D, ies. Cotransfection into Jurkat T cells of the IL-4 reporter
construct together with expression vectors containingthe IRF-1 and IRF-2 antibodies specifically supershifted
IRF-1 and IRF-2, respectively. These experiments dem- either the IRF-1 or the IRF-2 cDNA or the vector alone
showed a dose-dependent repression of the IL-4 pro-onstrate that the IL-4 promoter contains at least three
IRF binding sites. moter (Figure 4A). Crosstitrations of IRF-1 and IRF-2
also showed a persistent repression for all combinations
of IRF-1 and IRF-2 (Figure 4B). The repression was de-IRF-1 and IRF-2 Act as Repressors
of the IL-4 Promoter pendent on the absolute amount of IRFs but not on the
ratio of IRF-1 and IRF-2. The experiments demonstrateThe finding of three IRF binding sites prompted us to
further investigate the functional role of IRF-1 and IRF-2 that both IRF-2 and IRF-1 can act as repressors in the
context of the IL-4 promoter.in the context of IL-4 promoter activity. A luciferase
reporter construct containing up to 310 of the human We further investigated the functional importance of
the IRF sites on the IL-4 promoter and introduced differ-IL-4 promoter was used for transient transfection stud-
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Figure 4. Repression of IL-4 Promoter Activ-
ity by IRF-2 and IRF-1
Jurkat T cells were transiently transfected
with an IL-4 promoter (310/11) luciferase
construct together with the indicated
amounts of either IRF-1 or IRF-2 expression
vectors (A) or combinations of different
amounts of IRF-1 and IRF-2 (B). The empty
vector pCDNA3 was added to have equal
amounts of DNA in the transfections. After
overnight culture, the transfected cells were
split and stimulated with -CD3 and -CD28
or left unstimulated. pRSV -gal was used as
an internal control for transfection efficiency.
Luciferase and -galactosidase activities
were determined after 8 hr of stimulation. The
mean values and SD are representative of
three independent experiments.
ent combinations of mutations into these sites. IRF-2 is 45%–50%. In contrast, the activity of the IL-4 promoter
containing mutations of all three IRF sites was substan-constitutively present in Jurkat T cells (Li-Weber et al.,
1994). Transfection of the wild-type and the mutated tially less affected by IFN-. The experiments demon-
strate that all three IRF binding sites are involved inIL-4 promoter constructs into Jurkat T cells showed that
mutation of the IRF sites greatly enhanced the activity the IFN--mediated suppression of IL-4 expression in
normal T cells.of the IL-4 promoter in response to T cell activation
(Figure 5A). Cotransfection of the promoter constructs
with IRF expression vectors showed that each IRF site IRF-1 and IRF-2 Bind to the IL-4 Promoter In Vivo
Jurkat T cells constitutively express IRF-2 (Li-Weber etresponded to IRF-1- and IRF-2-mediated repression.
When all three IRF sites were mutated, the promoter al., 1994). A low level of IRF-1 was also detected in Jurkat
T cells by EMSA (Figure 6A). To determine whether IRF-1activity was no longer downregulated by IRFs (Figure
5A). These data demonstrate that all three sites are func- and IRF-2 indeed bound to the IL-4 promoter in vivo,
we used chromatin immunoprecipitation (ChIP) assaystional IRF sites and IRFs repress IL-4 promoter activity
through these three sites. in Jurkat T cells. The ChIP technique can establish
whether a known transcription factor truly binds in theTo further investigate whether the IRF sites are re-
quired for INF--mediated suppression of IL-4 transcrip- vicinity of a known regulatory element in living cells
(Parekh and Maniatis, 1999). PCR primers specific fortion, the wild-type and the three IRF-mutated IL-4 pro-
moter constructs, respectively, were transfected into the IL-4 promoter 336 to 40 (296 bp PCR product)
were used. To increase the levels of IRF-1 and IRF-2 infreshly isolated primary human T lymphocytes using a
liposome-based transfection system. Figure 5B shows Jurkat T cells, we transiently transfected Jurkat T cells
with IRF-1 and IRF-2 expression vectors. After overnightthe results from two different T cell donors. In the pres-
ence of IFN-, the activity of the wild-type IL-4 promoter recovery, the cells were stimulated with PMA and iono-
mycin for 3 hr and subsequently subjected to ChIPreporter constructs was reduced by approximately
Immunity
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Figure 5. Mutation Analysis of the IL-4 Pro-
moter
(A) The wild-type and the mutated IL-4 pro-
moter constructs were cotransfected with
0.75 g of either the IRF-1, the IRF-2, or the
empty vector pCDNA3 into Jurkat T cells. The
mutated sites are indicated in the left part
of the figure. pRSV -gal was included in all
transfections to control transfection effi-
ciency. After overnight culture, the trans-
fected cells were split and stimulated with
-CD3 and -CD28 or left unstimulated. Lu-
ciferase and -galactosidase activities were
determined after 8 hr of stimulation. The
mean values and SD are representative of
three independent experiments.
(B) The wild-type (wt) and the IRF-mutated
(mut) IL-4 promoter constructs were trans-
fected into freshly isolated primary human T
cells. After overnight culture, the transfected
cells were split and stimulated with -CD3
and -CD28 in the absence or presence of
100 U IFN- for a further 8 hr. Results from
two different donors are presented. The mean
values and SD are presented for two indepen-
dent transfections.
assays. The assays using -IRF-1 and -IRF-2 antibod- 1989). A weak binding of IRF-2 to the IL-4 promoter was
also observed. Therefore, IRF-1 and IRF-2 can bind toies showed that both factors bound to the IL-4 promoter
(Figure 6B). In control experiments, DNA-protein com- the IL-4 promoter upon IFN- stimulation.
plexes immunoprecipitated without antibodies did not
generate the 296 bp IL-4 promoter product (Figure 6B). Analysis of IL-4 Expression in IRF-1/ Naive
CD4 T CellsWe next investigated whether the IL-4 promoter inter-
acted with IRFs induced by IFN- in vivo. ChIP assays We further investigated whether IL-4 expression in mu-
rine T cells is regulated by IRFs in a manner similar towere carried out with freshly isolated peripheral blood
T lymphocytes stimulated with -CD3 and -CD28 in that in human T cells. Since in IFN-stimulated cells IRF-2
gene induction occurs only secondary to induction ofthe absence or presence of IFN-. A strong binding of
IRF-1 to the IL-4 promoter was observed when cells IRF-1 (Harada et al., 1989), IRF-1/ mice were used
to address this question. Upon primary stimulation bywere activated in the presence of IFN- (Figure 6C).
IRF-2 expression is regulated by IRF-1 (Harada et al., -CD3, purified naive CD4 T cells from IRF-1/ but not
IFN- Represses IL-4 Expression
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Figure 6. IRF-1 and IRF-2 Bind to the IL-4
Promoter In Vivo
(A) Detection of IRF-1 and IRF-2 in Jurkat
T cells. EMSA was performed using nuclear
extracts of Jurkat T cells in the absence ()
or presence of -IRF-1- or -RFF-2-specific
antibodies as indicated. The specific IRF/
DNA complexes and the supershifted bands
are indicated by arrows.
(B) In vivo binding of IRF-1 and IRF-2 to the
IL-4 promoter was assessed by ChIP with
Jurkat T cells transfected with IRF-1 and
IRF-2 expression vectors. DNA-protein com-
plexes were immunoprecipitated without an-
tibodies (No Ab) or with antibodies specific
for IRF-1 and IRF-2 as indicated. Specific
PCR amplified 296 bp of the IL-4 promoter.
(C) In vivo binding of IRF-1 and IRF-2 to the
IL-4 promoter in peripheral blood T cells upon
IFN- stimulation. The ChIP assays were car-
ried out as in (B). Peripheral T cells were stim-
ulated by -CD3 and -CD28 for 4 hr in the
absence () or presence () of 300 U IFN-
(added 12 hr before stimulation) as indicated.
from IRF-1/ and IRF-1/ mice produced significant repressor. However, an inhibitory domain was recently
identified within the N-terminal 60 amino acids of IRF-1amounts of IL-4 (Table 1), while IFN- expression was
stronger in IRF-1/ and IRF-1/ than in IRF-1/ CD4 and was shown to have inhibitory transcriptional activity
(Kirchhoff et al., 2000). In our experiments we show thatT cells (Table 1). These data strongly suggest an inhibi-
tory role of IRF-1 in IL-4 expression in the murine CD4 IRF-1 intrinsically represses IL-4 promoter activity at all
concentrations tested and at varying combinations ofT cells. However, in contrast to the human system, appli-
cation of IFN- or -IFN- antibodies did not influence IRF-1 and IRF-2. This suggests that IRF-1 functions to-
gether with IRF-2 (since all complexes bound on theIL-4 expression levels in -CD3-stimulated naive CD4
T cells taken from any of the mice tested including wild- IL-4 IRF binding sites contain both IRF-1 and IRF-2) as a
repressor of IL-4 transcription. This finding is consistenttype mice (data not shown), suggesting differences be-
tween the human and murine systems (see Discussion). with the previous observation that the IRF-1/ T cells
fail to mount Th1 responses and, instead, exclusively
undergo Th2 differentiation (Matsuyama et al., 1993; Lo-Discussion
hoff et al., 1997; Taki et al., 1997). We show that naive
CD4 T cells from IRF-1/ but not from IRF-1/ andIn this study, we show that IFN- downregulates IL-4
IRF-1/ mice produce significantly higher levels of IL-4production in -CD3-induced human primary T cells in a
(Table 1). These data demonstrate that IRF-1 acts as adose-dependent manner. Repression of IL-4 production
repressor for the IL-4 gene also in the mouse. We alsoby IFN- occurs at the transcriptional level via repres-
investigated the effect of IFN- on IL-4 expression insion of IL-4 promoter activity by the IFN--inducible
murine T cells. However, in contrast to human T cells,factors IRF-1 and IRF-2. In addition, we identified three
the presence of IFN- or -IFN- antibodies had noIRF binding sites that are involved in repression of the
influence on the IL-4 expression levels in -CD3-stimu-IL-4 promoter by IFN-. Our data demonstrate that IFN-
lated murine CD4 T cells from either IRF-1/, IRF-1/,exerts a direct negative feedback effect on IL-4 gene
or IRF-1/ mice (data not shown). This may be ex-expression. Therefore, IFN- may assist Th1 response
plained by the fact that in contrast to human T cells,by direct attenuation of IL-4 expression.
where expression of IRF-1 mRNA (unpublished data)IRF-1 was originally identified as a transcriptional acti-
and IRF-1 DNA binding activity (Figure 4) are not influ-vator of the human IFN- gene (Miyamoto et al., 1988).
enced by T cell receptor stimulation, expression of IRF-1Consequently, IRF-1 was found to activate IFN-responsive
mRNA as well as IRF-1 protein in murine T cells hasgenes (for review see Stark et al., 1998). In general, IRF-1
been shown to be already strongly induced upon T cellis considered to be a transcriptional activator. So far,
activation via the TCR alone (Miyamoto et al., 1988;IRF-1 has not been reported to act as a transcriptional
Nelson et al., 1996). Thus, this discrepancy might be
due to the fact that no further enhancement of IRF-1
expression in -CD3-stimulated murine T cells is possi-Table 1. IL-4 Protein Expression by Murine CD462L T Cells
ble by adding IFN-.
IFN- (pg/ml) IL-4 (pg/ml)Cytokines Unlike IRF-1, IRF-2 was originally described as an
antagonist that represses IRF-1-dependent transcrip-Genotypes IRF-1/ IRF-1/ IRF-1/ IRF-1/ IRF-1/ IRF-1/
tional activity by binding to the same sites (Harada et
25,000 28,500 2400 30 30 1200
al., 1990, 1994). Therefore, IRF-2 has been considered
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was performed with the MACS CD4 Multisort Kit (Miltenyi Biotec,to be a transcriptional repressor. However, evidence
Bergisch Gladbach, Germany) according to the manufacturer’s in-showed that IRF-2 also functions as a transactivator
structions. Purity (95%) was confirmed by FACS staining with(Vaughan et al., 1995, 1998). Analysis of IRF-2/ mice
-CD4 antibodies (BD Pharmingen, Heidelberg, Germany). Naive
showed that, like IRF-1, IRF-2 is required for normal CD462L T cells were purified from lymph nodes and spleens of
generation of Th1 responses (Lohoff et al., 2000). Since mice (4–8 weeks of age) and stimulated with immobilized -CD3
antibody as previously described (Lohoff et al., 2000) for 96 hr.the phenotype of IRF-2/ mice is similar to those of
IRF-1/ mice in regard to their bias toward a Th2-medi-
Culture and Stimulation of Primary Human T Lymphocytesated immune response and with respect to the defect
and Cell Linesin Th1-mediated immune responses, it has been sug-
Primary human T lymphocytes and Jurkat T cells were cultured
gested that IRF-1 and IRF-2 may act as functional ago- in RPMI supplemented with 10% heat-inactivated fetal calf serum
nists rather than antagonists on some IFN--responsive (Gibco BRL, Eggenstein, Germany), 10 mM HEPES (Gibco BRL,
genes (Lohoff et al., 2000). In our studies, we show that Eggenstein, Germany), and 100 g gentamycin/ml. Stimulation was
performed by 3 g/ml -CD3 (OKT3) and 1.5 g/ml -CD28 cross-IRF-2 transcriptionally represses the IL-4 promoter. Nei-
linked with 1g/ml protein A (Sigma-Aldrich, Taufkirchen, Germany).ther antagonist nor synergistic effects were seen when
Human IFN- and monoclonal -human IFN- antibody were pur-both IRF-1 and IRF-2 were combined in cotransfection
chased from Roche Diagnostics GmbH (Mannheim, Germany) and
studies. Since the previous IRF-2/ studies mainly con- R&D Systems GmbH (Wiesbaden, Germany), respectively.
centrated on defects in the polarization to Th1 cells and
in the Th1-mediated immune response (Lohoff et al., ELISA
2000), it would be worthwhile to further investigate IL-4 Supernatants from cultures treated as described in the text were
measured for cytokine levels by ELISA using ELISA kits for humanand other Th2 cytokine expressions in the IRF-2/mice.
IL-4 (BD Pharmingen, Heidelberg, Germany) according to the manu-IRF-1 and IRF-2 are the best characterized members
facturer’s instructions.of the IRF family. The family has now expanded to in-
clude seven additional members (Mamane et al., 1999;
RT-PCR
Tanaka and Taniguchi, 2000). All IRF family members RNA was isolated using the RNEasy kit (Qiagen GmbH, Hilden, Ger-
show remarkable sequence homology in the DNA bind- many) according to the manufacturer’s instructions. One microgram
of total RNA was reverse transcribed using the Perkin Elmer Gene-ing domain. Therefore, IFN--mediated suppression of
Amp RNA PCR kit (Foster City, CA). Aliquots were amplified in aIL-4 might also involve other IFN--inducible IRFs such
DNA thermocycler (Stratagene, Heidelberg, Germany) with 2.5 Uas IRF-8 (also named ICSBP) and IRF-9 (also called p48/
recombinant Taq polymerase (Sigma, St. Louis, MO) in a 50 l reac-ISGF3). Unlike IRF-1 and IRF-2 which are expressed
tion. Thirty cycles were performed, each consisting of the following
in all cell types, IFR-8 expression is restricted to the conditions: 94C, 1 min; 56C, 1 min; and 72C, 1 min. Primers for
macrophage and lymphoid cell lineages. IRF-8 is in- human IL-4 and -actin have been described previously (Li-Weber
et al., 1998). Amplification products were separated by electropho-duced by IFN- but not by IFN-/ (Driggers et al., 1990;
resis on 1.2% agarose gels.Nelson et al., 1996). The DNA binding activity of IRF-8
by itself is very weak but is dramatically increased by
Preparation of IRF-1 and IRF-2 Proteinits interaction with IRF-1 and IRF-2 (Sharf et al., 1995).
TNT Quick Coupled Transcription/Translation Systems (Promega
IRF-8/ mice, like IRF-1/ and IRF-2/ mice, show a Corporation, Madison, WI) was used to obtain in vitro-translated
defective Th1-type-immune response (Hochrein et al., IRF-1 and IRF-2 protein according to manufacturer’s instructions.
2000). IRF-1 and IRF-2 plasmids used for the in vitro transcription/transla-
tion were published previously (Harada et al., 1994; Kirchhoff et al.,IRF-9 is also an IFN--inducible IRF. IRF-9 by itself
1993).has no transactivity and usually exerts its transcriptional
effects exclusively in association with signal transducer
EMSAand activator of transcription (STAT) 1 and 2 activated
Nuclear extracts were prepared as described previously (Li-Weber
through specific phosphorylation events by type I IFNs et al., 1994). The following oligonucleotides were used as probes
(IFN/) (Bluyssen et al., 1996). In IRF-9/ cells the in EMSA: 92/112 TGG CCC CAA GTG ACT GAC AA, 180/200
induction of the antiviral state by IFNs is dramatically AAA GGT TTC ATT TTC CTA TT, 280/304 CTA TGC AAA GCA
AAA AGC CAG CAG CAG CCC CAA GCT, IRF consensus TCACTTTimpaired (Kimura et al., 1996). Since IRF-9 is the main
CACTTTCACTT. For binding reactions, 0.5 g of nuclear extractDNA binding component of the IRF-9/STAT1/STAT2 tri-
was incubated with reaction buffer (Li-Weber et al., 1994) in themolecule structurally related to IRF-1, it may be worth-
presence or absence of antibody for 10 min at room temperature.
while to further analyze the cytokine profiles of IRF-9/ Then the radiolabeled probe (	20,000 cpm) was added and incu-
mice after IFN- treatment. bated for an additional 20 min. The binding products were analyzed
In summary, we describe a novel negative feedback by electrophoresis on 5% polyacrylamide gel in 0.5
 TBE buffer.
Gels were dried and analyzed by autoradiography.loop between IFN-, a hallmark of Th1 cells, and IL-4,
a hallmark of Th2 cells. In primary human T lymphocytes,
Plasmid ConstructionIFN--mediated induction of IRF-1 and IRF-2 leads to
pLuc-IL4 310/11 was constructed by cutting the 310/11 IL-4repression of the IL-4 promoter activity via three distinct
fragments from the CAT-IL4 310/11 construct (Li-Weber et al.,
promoter sites. Our study thus describes another impor- 1992) and recloning into the multiple-cloning site of the pLuc plasmid
tant feature of the complex regulation of the cytokine (kindly supplied by Dr. T. Wirth, Institute of Medicine and Cell Re-
search, Wu¨rzburg, Germany). Mutations were performed using thenetwork.
QuikChange mutagenesis kit (Stratagene, La Jolla, CA) according
to the manufacturer’s instructions. The primers used for mutationsExperimental Procedures
were: IRF-A mu-s 5-GGTGCTGATTGGCCCCGCACGCCTGACAAT
CTGGTGTAACG-3, IRF-A mu-a 5-CGTTACACCAGATTGTCAGGCPurification of Primary T Lymphocytes and CD4 T Lymphocytes
Human peripheral T cells were prepared and activated as described GTGCGGGGCCAATCAGCACC-3, IRF-B mu-s 5-GTAGTTAATTTT
TTAAAAAGGTGCACGCTTCCTATTGGTCTGATT TCACAGG-3, IRF-Bpreviously (Klas et al., 1993). Purification of CD4 T lymphocytes
IFN- Represses IL-4 Expression
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mu-a 5-CCTGTGAAATCAGACCAATAGGAAGCGTGCACCTTTTTA presenting cell to inhibit cytokine production by Th1 cells. J. Immu-
nol. 146, 3444–3451.AAAAAT TAACTAC-3, IRF-C mu-s 5-GCCTCTCCCTTCTATGCA
CGT GCGAAAGCCAGCAGCAGCCCC-3, IRF-C mu-a 5-GGGGCTG Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M.,
CTGCTGGCTTTCGCACGTGCATAGAAGGGAGAGGC-3. Under- Furia, A., Miyata, T., and Taniguchi, T. (1989). Structurally similar
lined nucleotides represent mutated sites. All mutations were con- but functionally distinct factors, IRF-1 and IRF-2, bind to the same
firmed by sequence analysis. The IRF-1 (Miyamoto et al., 1988) and regulatory elements of IFN and IFN-inducible genes. Cell 58,
IRF-2 (Harada et al., 1994) expression vectors were kindly supplied 729–739.
by Dr. T. Tanigushi (Osaka University, Japan).
Harada, H., Willison, K., Sakakibara, J., Miyamoto, M., Fujita, T., and
Taniguchi, T. (1990). Absence of type I IFN system in EC cells:
Transient Transfections transcriptional activator (IRF-1) and repressor (IRF-2) genes are de-
Jurkat T cells were transiently transfected by electroporation. In all velopmentally regulated. Cell 63, 903–913.
transfection experiments 10 g of reporter construct was trans- Harada, H., Takahashi, E., Itoh, S., Harada, K., Hori, T.A., and Tani-
fected using a Bio-Rad Gene Pulser (Bio-Rad GmbH, Mu¨nchen, guchi, T. (1994). Structure and regulation of the human interferon
Germany) set at 960 microfarads, 240 V. To transfect primary human regulatory 1 (IRF-1) and IRF-2 genes: implications for a gene network
T lymphocytes, DOTAP Liposomal Transfection Reagent (Roche in the interferon system. Mol. Cell. Biol. 14, 1500–1509.
Diagnostics GmbH, Mannheim, Germany) was used according to
Ho, I.-C., Hodge, M.R., Rooney, J.W., and Glimcher, L.H. (1996). Thethe manufacturer’s instructions. To control for transfection effi-
proto-oncogene c-maf is responsible for tissue-specific expressionciency, cells were cotransfected with 1 g of pRSV -gal (a kind
of interleukin-4. Cell 85, 973–983.gift from Dr. L. Schmitz, German Cancer Research Center, Germany).
Ho, I.-C., Lo, D., and Glimcher, L.H. (1998). C-maf promotes Th2Luciferase activity was determined in 10 ml of cell extract using the
and attenuates Th1 differentiation by both IL-4 dependent and inde-luciferase assay substrate (Promega, Mannheim, Germany) with a
pendent mechanisms. J. Exp. Med. 188, 1859–1866.Duolumat LB9507 luminometer (Berthold, Freiburg, Germany).
-galactosidase activity was determined by incubation of 25 l of Hochrein, H., O’Keeffe, M., Luft, T., Vandenabeele, S., Grumont,
cell extracts in buffer (final volume 300 l) containing 100 mM R.J., Maraskovsky, E., and Shortman, K. (2000). Interleukin (IL)-4 is
Na2HPO4, 100 mM NaH2PO4 (pH 7.5), 1 mM MgCl2, 45 mM a major regulatory cytokine governing bioactive IL-12 production
-mecaptoethanol, 1 mg/ml o-nitrophenyl--D-galactopyranoside, by mouse and human dendritic cells. J. Exp. Med. 192, 823–834.
and 1 l -galactosidase) at 37C for 30 min. The reaction was Hodge, M.R., Ranger, A.M., Charles de la Brousse, F., Hoey, T.,
stopped by adding 500 l 1 M Na2CO3 and measured by photometer Grusby, M.J., and Glimcher, L.H. (1996a). Hyperproliferation and
at OD600. dysregulation of IL-4 expression in NF-ATp-deficient mice. Immunity
4, 397–405.
Chromatin Immunoprecipitation (ChIP) Assays Hodge, M.R., Chun, H.J., Rengarajan, J., Alt, A., Lieberson, R., and
PMA- (10 ng/ml) and ionomycin- (1 M) stimulated Jurkat T cells Glimcher, L.H. (1996b). NFAT-driven interleukin-4 transcription po-
(2 
 107) or -CD3- (coated with 30 g/ml) and -CD28- (5 g/ml) tentiated by NIP45. Science 274, 1903–1905.
stimulated peripheral blood T cells (1 
 107) were crosslinked by
Holtschke, T., Lo¨hler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer,
formaldehyde (final concentration  1%). The cells were lysed and
F., Lou, J., Knobeloch, K.P., Gabriele, L., Waring, J.F., et al. (1996).
sonicated essentially as described (Strahl-Bolsinger et al., 1997).
Immunodeficiency and chronic myelogenous leukemia-like syn-
The chromatin was immunoprecipitated with 2 g of -IRF-1 or
drome in mice with a targeted mutation of the ICSBP gene. Cell 87,
-IRF-2 antibodies for 2 hr at 4C. Following deproteination and
307–317.
reversal of crosslinks as described (Strahl-Bolsinger et al., 1997),
Kaplan, M.H., Schindler, U., Smiley, S.T., and Grusby, M.J. (1996a).the presence of selected DNA sequences was assessed by PCR.
Stat6 is required for mediating responses to IL-4 and for the develop-The primers used for the IL-4 promoter were: (336)-5-CAACAAAT
ment of Th2 cells. Immunity 4, 313–319.TCGGACACCTG-3 and (40)-5-GCTGAAACCGAGGGAAAAT-3
Kaplan, M.H., Sun, Y.L., Hoey, T., and Grusby, M.J. (1996b). Impaired(296 bp product).
IL-12 responses and enhanced development of Th2 cells in Stat4-
deficient mice. Nature 382, 174–177.Acknowledgments
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